Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Levomilnacipran
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Zydus Receives Tentative Approval from The USFDA For Levomilnacipran Extended-Release Capsules
Details : Fetzima® generic version (levomilnacipran) is an oral extended release capsule which selectively inhibits serotonin and norepinephrine reuptake (SNRI) and it has shown positive results for the treatment of major depressive disorder (MDD) in adults.
Brand Name : Levomilnacipran-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 16, 2023
Lead Product(s) : Levomilnacipran
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?